Additional file 1 of Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis
Creators: name: Cortes, Javier
name: Haiderali, Amin
name: Huang, Min
name: Pan, Wilbur
name: Schmid, Peter
name: Akers, Katherine G.
name: Park, Julie E.
name: Frederickson, Andrew M.
name: Fasching, Peter A.
name: O’Shaughnessy, Joyce
Publisher: name: figshare
Year: 2023
Subjects: Information Systems not elsewhere classified
Developmental Biology
Cancer
Science Policy

description: Additional file 1: Additional Table 1. PRISMA 2020 checklist. Additional Table 2. Search strategy for EMBASE 1974 to 2022 April 20.Additional Table 3. Search strategy for Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to April 20, 2021.Additional Table 4. Search strategy for EBM Reviews - Cochrane Central Register of Controlled Trials March 2022. Additional Table 5. Trials identified in the systematic review.Additional Table 6. Trials included in the feasibility assessment and network meta-analysis.Additional Table 7. Treatment characteristics of included trials. Supplementary Table 8. Baseline patient characteristics of included trials.Additional Table 9. Definitions of pathological complete response, overall survival, and event-free survival used in the included trials.Additional Table 10. Data sources for feasibility assessment and network meta-analysis. Additional Figure 1. Results of network meta-analysis for event-free survival based on time-varying hazard ratios (constant hazards with p1=0.5, p2=0). Additional Figure 2. Best-fitting model: Results of network meta-analysis for overall survival based on constant hazard ratio model with p1=0, p2=0.Additional Figure 3. Second best-fitting model: Results of network meta-analysis for overall survival based on second-order fractional polynomial model with p1=0, p2=0.5; scale and second shape. Additional Table 11. Model fit estimate for network meta-analysis for event-free survival with parametric survival models. Additional Table 12. Estimated hazard ratios for event-free survival versus paclitaxel followed by anthracycline + cyclophosphamide at select time points based on time-varying hazard ratio assumption (constant hazard ratio with p1=0.5, p2=0). Additional Table 13. Basic parameter estimates of constant hazard ratio model with p1=0.5, p2=0 for event-free survival. Additional Table 14. Model fit estimate for network meta-analysis for overall survival with parametric survival models. Additional Table 15. Best-fitting model for overall survival: Estimated hazard ratios versus paclitaxel followed by anthracycline + cyclophosphamide at select time points based on time-varying hazard ratio assumption (constant hazard ratio with p1=0, p2=0). Additional Table 16. Best-fitting model for overall survival: Basic parameter estimates of constant hazard ratio model with p1=0, p2=0. Additional Table 17. Second best-fitting model for overall survival: Estimated hazard ratios versus paclitaxel followed by anthracycline + cyclophosphamide at select time points based on time-varying hazard ratio assumption (second-order fractional polynomial with p1=0, p2=0.5). Additional Table 18. Second best-fitting model for overall survival: Basic parameter estimates of second-order polynomial model with p1=0, p2=0.5. Additional Figure 4. Network of evidence for event-free survival and overall survival including CALGB 40603 (Alliance). Arrows (➔) indicate where treatment was administered sequentially, with treatments to the left of the arrow administered first. The orange circle denotes the primary treatment regimen of interest. Anthra includes doxorubicin and epirubicin, which were assumed to be equivalent. Anthra = anthracycline; bev = bevacizumab; carb = carboplatin; cyclo = cyclophosphamide; doc = docetaxel; nab-pac = nab-paclitaxel; pac = paclitaxel; pembro = pembrolizumab; veli = veliparib. Additional Table 19. Results of network-analysis for event-free survival including CALGB 40603 (Alliance). Additional Table 20. Results of network-analysis for event-free survival including CALGB 40603 (Alliance).